MedPath

Tianjin Medical University Cancer Institute & Hospital

🇨🇳China
Ownership
-
Employees
-
Market Cap
-
Website

Metformin Plus Sorafenib for Advanced HCC

Phase 2
Conditions
Hepatocellular Carcinoma
Interventions
First Posted Date
2016-02-03
Last Posted Date
2016-02-03
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
82
Registration Number
NCT02672488
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, China

Endocrine Therapy With or Without Cryoablation for Stage IV Prostate Cancer

Not Applicable
Conditions
Stage IV Prostate Cancer
Interventions
Procedure: cryoablation
Drug: luteinizing-hormone releasing-hormone (LHRH) agonist
First Posted Date
2015-11-26
Last Posted Date
2017-06-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
120
Registration Number
NCT02615223
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Cryoablation Therapy or Radiotherapy Therapy for Stage III Prostate Cancer

Not Applicable
Conditions
Stage III Prostate Cancer
Interventions
Procedure: Cryoablation therapy
Radiation: External beam radiation therapy
Drug: luteinizing-hormone releasing-hormone (LHRH) agonist
First Posted Date
2015-11-16
Last Posted Date
2017-06-12
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
240
Registration Number
NCT02605226
Locations
🇨🇳

Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Evaluation of the Relationship of TOP2α Expression and Effect of Non Dose-dense Chemotherapy for Breast Cancer

Recruiting
Conditions
Breast Cancer
First Posted Date
2015-07-23
Last Posted Date
2015-07-23
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
800
Registration Number
NCT02506361
Locations
🇨🇳

Jin Zhang, Tianjin, China

Recombinant Human Endostatin Combined With NP in Neoadjuvant Chemotherapy of Stage ⅢA NSCLC

Phase 4
Completed
Conditions
Non Small Cell Lung Cancer
Interventions
First Posted Date
2015-07-14
Last Posted Date
2015-07-14
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
30
Registration Number
NCT02497118
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

Monosialotetrahexosylganglioside for Treatment of Oxaliplatin Induced Neurotoxicity in Gastrointestinal Cancer

Phase 3
Completed
Conditions
Neurotoxicity
Interventions
Drug: placebo
Drug: GM
Drug: oxaliplatin-based chemotherapy
First Posted Date
2015-07-01
Last Posted Date
2018-02-05
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
145
Registration Number
NCT02486198
Locations
🇨🇳

TianjinCIH, Tianjin, Tianjin, China

Study on Effectiveness and Safety of Hepatocellular Carcinoma Patients Treated With CyberKnife

Phase 2
Conditions
Liver Neoplasms
Interventions
Radiation: CyberKnife
First Posted Date
2015-02-13
Last Posted Date
2016-10-07
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
117
Registration Number
NCT02363218
Locations
🇨🇳

Tianjin Medical University Cancer Institute & Hospital, Tianjin, Tianjin, China

Clinical Trial on the Efficacy and Safety of Chining Decoction in the Treatment of Radiation Stomatitis

Phase 3
Completed
Conditions
Head and Neck Cancer
Interventions
First Posted Date
2014-11-27
Last Posted Date
2015-12-22
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
70
Registration Number
NCT02303197
Locations
🇨🇳

Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

A Trial to Evaluate the Superior Mesenteric Vein (14V) Lymphadenectomy for Distal Advanced Gastric Cancer

Conditions
Gastric Cancer
Interventions
Procedure: Dissection of the Superior Mesenteric Vein Lymph Node
First Posted Date
2014-10-23
Last Posted Date
2015-12-09
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
510
Registration Number
NCT02272894
Locations
🇨🇳

Department of Gastrointestinal Medical Oncology, Tianjin Medical University Cancer Hospital, Tianjin, Tianjin, China

Molecular Phenotype Changes and Personalized Treatment for CRPC

Not Applicable
Conditions
Hormone Refractory Prostate Cancer
Interventions
Drug: DP & Targeted drugs
Drug: EP & Targeted drugs
First Posted Date
2014-08-05
Last Posted Date
2014-08-05
Lead Sponsor
Tianjin Medical University Cancer Institute and Hospital
Target Recruit Count
150
Registration Number
NCT02208583
Locations
🇨🇳

Department of Interventional Oncology, Tianjin Medical University Cancer Institute and Hospital, Tianjin, Tianjin, China

© Copyright 2025. All Rights Reserved by MedPath